The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...
Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in 2023. This is despite growing availability of a highly effective HIV ...
The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...
– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.
UN World Children's Day on Nov 20 is an annual reminder that every child deserves the chance not just to survive, but to ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback